婴幼儿型血管瘤(Infantile hemangioma,IH)是儿童期常见疾病,发病率约为4%,可见于全身各个部位,头面部占40%~60%。临床治疗中涉及多个学科,治疗方法尚不统一,文献报道主要有手术、药物(口服、局部注射,少数情况下静脉给药)、同位素、冷冻、激光、光动力、铜针通电、微波治疗、血管介入治疗,以及定期观察随访等~([1])。2008年Leaute-Labreze等~([2])报道口服普萘洛尔治疗11例IH取得良好疗效,其应用已逐渐成为临床一线选择。但其治疗机制仍不清楚,且对幼年群体安全性研究缺乏,影响了其临床推广。1机制的思考相对临床使用及观察的热度而言,目前普萘洛尔治疗婴幼儿型血管瘤作用机制研究仍 Infantile hemangioma (IH) is a common childhood disease, the incidence rate of about 4%, can be found in all parts of the body, head and face accounted for 40% to 60%. There are many subjects involved in clinical treatment, the treatment methods are not uniform, the literature mainly reported surgery, drugs (oral, local injection, a few cases of intravenous administration), isotope, freezing, laser, photodynamic force, copper needle electrotherapy, microwave therapy , Vascular intervention, and regular observation follow-up ~ ([1]). 2008 Leaute-Labreze et al ~ ([2]) reported oral propranolol treatment of IH in 11 cases achieved good effect, its application has gradually become a clinical first-line choice. However, its mechanism of treatment is still unclear, and the lack of research on the safety of juvenile populations has affected its clinical promotion. 1 mechanism of the relative clinical use and observation of the heat, the current mechanism of action of propranolol infant and hemangioma research is still